BasicFintech
SME IPOupcomingNSE SME

Pramodini Medicare IPO

Pramodini Medicare IPO is an SME issue scheduled to open for subscription on — and closed on —. The issue aggregates ₹45.1 Cr.

Price Band
TBA
GMP
Subscription
Listing

Overview

Pramodini Medicare IPO is an SME issue scheduled to open for subscription on — and closed on —. The issue aggregates ₹45.1 Cr.

IPO Details

Pramodini Medicare IPO is a Small and Medium Enterprise (SME) initial public offering scheduled to open for subscription on NSE SME. The issue has a price band of TBA per equity share with a lot size of TBA shares, translating to a minimum retail investment of TBA.

The issue aggregates ₹45.1 Cr, and subscription dates are yet to be announced. Allotment is expected on and the equity shares are scheduled to list on .

Type
SME
Status
upcoming
Price band
TBA
Face value
₹10 (typical)
Lot size
Min investment (Retail)
TBA
Issue size
₹45.1 Cr
Fresh issue
OFS
Exchange
NSE SME
ISIN
TBA

Market Lot

Market lot details will be available once the price band and lot size are finalised in the Red Herring Prospectus.

IPO Reservation

Per SEBI guidelines, Pramodini Medicare IPO reserves shares across investor categories as follows. Final allotment percentages may vary slightly based on the final issue document.

Category% ReservedNotes
QIBUp to 50%Mutual funds, FIIs, banks
NII / HNIUp to 15%Bids ≥ ₹2 lakh
RetailAt least 35%Bids up to ₹2 lakh

Important Dates

  1. Issue Open
    · Subscription opens
  2. Issue Close
    · Subscription closes
  3. Allotment
    · Basis of allotment finalised
  4. Refunds Initiated
    · Funds released for non-allottees
  5. Listing Date
    · Shares debut on the exchange

Grey Market Premium

Grey Market Premium for Pramodini Medicare is yet to be tracked. We update GMP from multiple grey market sources during the subscription window. Bookmark this page and check IPO GMP Today for live updates.

Subscription Status

Pramodini Medicare IPO subscription tracking will go live once the subscription window opens. Category-wise data (Retail / NII / QIB / Employee) will be available on IPO Subscription Status.

Allotment Status

Pramodini Medicare IPO allotment will be finalised by the registrar (Purva Sharegistry India) on . Check your allotment status using your PAN, application number, or DP ID via our allotment status checker or directly on the registrar's website.

If allotment fails, the blocked funds via ASBA / UPI mandate are released back within 24-48 hours. Applying through multiple demat accounts in family members' names improves chances on oversubscribed IPOs.

About Pramodini Medicare

Pramodini Medicare Limited is a diagnostic-services provider offering technology-enabled diagnostic services across three segments: radiology (CT/MRI/ultrasound/X-ray imaging), clinical laboratory (pathology + biochemistry + hematology), and nuclear medicine (PET-CT/SPECT diagnostic imaging). The multi-modality positioning is meaningfully differentiated from typical pathology-only diagnostic operators. Indian diagnostic-services has been one of the structurally strong healthcare sub-segments through 2020-26. Demand drivers include post-COVID diagnostic-capacity expansion across large urban populations, the formalisation of small unorganised single-doctor labs into chain operators (Dr Lal PathLabs, Metropolis, SRL Diagnostics ecosystem), PMJAY + state-insurance scheme expansion driving public-sector diagnostic demand, and the rising prevalence of chronic disease (diabetes, cardiovascular, oncology) requiring multi-modality diagnostic workups. Nuclear-medicine and PET-CT specifically benefit from oncology-prevalence increase and the broader cancer-screening category growth. 9-month FY26 financials (April-December 2025) are strong: revenue ₹44.4 crore with PAT ₹12.5 crore. PAT margin at ~28% is exceptional — materially above typical diagnostic-chain operators (12-18% PAT margin range). The premium margin profile likely reflects the radiology + nuclear-medicine mix (higher per-test pricing than commoditised pathology) combined with operational-efficiency from technology-enabled workflow. The ₹45.1 crore NSE SME IPO is structured as 0.54 crore fresh + 0.05 crore OFS (~92% fresh / 8% OFS). DRHP filed with NSE Emerge on 23 April 2026. Lead manager Smart Horizon Capital Advisors and registrar Purva Sharegistry India indicate SME book-build setup.

Promoter & Holding Pattern

The promoter and promoter group hold the majority stake in Pramodini Medicare prior to the IPO. Post-listing, this percentage will reduce as new equity shares are issued to the public. Detailed pre-IPO and post-IPO promoter holding data will be updated once the Red Herring Prospectus is finalised with SEBI.

Objects of the Issue

Pramodini Medicare IPO proceeds will be utilised across the following objectives, as disclosed in the Red Herring Prospectus:

PurposeAmount (₹ Cr)% of Issue
Equipping existing and planned diagnostic centres
Pursuing growth through acquisitions
General corporate purposes

Financial Performance

Three-year financial performance for Pramodini Medicare (amounts in ₹ Cr):

PeriodRevenueExpensePATTotal AssetsNet Worth
9M FY2644.412.5

Valuation Snapshot

RoE
RoCE
EBITDA Margin
PAT Margin
28.15%
Debt/Equity
EPS
P/E Ratio
RoNW
NAV

Peer Comparison

Listed peers in the Healthcare sector with key valuation metrics:

CompanyEPS (₹)P/E RatioRoNW (%)NAV (₹)Income (₹ Cr)
Dr. Lal PathLabs
Metropolis Healthcare
Vijaya Diagnostic Centre

Anchor Investors

Anchor investor bidding for Pramodini Medicare typically opens one working day before the issue opens to the public. Anchor investors — mutual funds, FIIs, sovereign wealth funds, and insurance companies — collectively subscribe to a portion of the QIB segment. Their participation signals institutional confidence. Anchor list and total amount will be updated once SEBI publishes the anchor filing.

Lead Managers (Merchant Bankers)

  • Smart Horizon Capital Advisors

IPO Registrar

The registrar processes all bid applications, finalises the basis of allotment, manages refunds, and credits allotted shares to successful applicants' demat accounts.

Editorial Review

Pramodini Medicare filed DRHP with NSE Emerge on 23 April 2026 for a ₹45.1 crore IPO — 0.59 crore equity shares total with ~92% fresh + ~8% OFS structure (0.54 cr fresh + 0.05 cr OFS). The 92% fresh-issue share is investor-friendly capital deployment. The business positioning is multi-modality technology-enabled diagnostics — radiology + clinical lab + nuclear medicine. The multi-modality combination is structurally differentiated from typical pathology-only diagnostic SMEs. Listed mainboard peers Dr Lal PathLabs, Metropolis Healthcare and Vijaya Diagnostic Centre all operate at vastly larger scale but predominantly in clinical-laboratory pathology rather than the multi-modality mix Pramodini operates. The 9M FY26 financials are exceptional. Revenue ₹44.4 crore with PAT ₹12.5 crore translates to ~28% PAT margin — materially above typical diagnostic-chain operators (12-18% PAT margin range). The premium margin profile likely reflects the radiology + nuclear-medicine mix (higher per-test pricing than commoditised pathology) combined with operational-efficiency from technology-enabled workflow. What's working: 28% PAT margin is exceptional — top-decile for diagnostic-services operators; multi-modality differentiation creates per-customer revenue upside vs pure-pathology peers; 92% fresh-issue + acquisition-funded growth strategy reaches operating business; capital deployment for diagnostic-centre equipment expansion + acquisitions; nuclear-medicine + PET-CT segment benefits from oncology-prevalence increase and cancer-screening category growth. What's concerning: NSE Emerge structural liquidity constraints; 9M FY26 financials are partial-year — full FY26 needs to validate the margin trajectory; competitive pressure from mainboard diagnostic leaders (Dr Lal PathLabs, Metropolis) entering multi-modality segments at scale; nuclear-medicine equipment-and-radiopharmaceutical cost pressure; substantial public-data gap on FY24 + FY25 full-year financials, exact price band, dates, anchor list. Subscribe pre-RHP. Exceptional 28% PAT margin + multi-modality positioning + 92% fresh-issue + acquisition-runway capital deployment create a high-conviction SME thesis. Wait for full RHP with FY25 audited financials and price band. Sizing modest given NSE Emerge structural constraints despite exceptional fundamentals.

How to Apply for Pramodini Medicare IPO

  1. Open broker app — Zerodha, Upstox, Angel One, Groww, 5paisa, ICICI Direct, or any other SEBI-registered broker. Navigate to the IPO section.
  2. Select Pramodini Medicare IPO during the bidding window ().
  3. Enter bid details — minimum TBA shares per lot. Retail investors are recommended to bid at cut-off price (upper band).
  4. Submit UPI ID linked to a SEBI-approved bank.
  5. Approve UPI mandate from your UPI app within the deadline. Bid amount is blocked, not debited.
  6. Await allotment on .
  7. Listing day — shares list on NSE SME on .

Risk Factors

1. NSE Emerge structural liquidity constraints. 2. 9M FY26 financials are partial-year — full FY26 needs to validate margin trajectory and growth-rate sustainability. 3. Competitive pressure from mainboard diagnostic leaders entering multi-modality segments at scale. 4. Nuclear-medicine equipment + radiopharmaceutical cost pressure — input costs can compress margins if procurement-cycle pricing shifts. 5. Diagnostic-centre acquisition-execution risk — IPO proceeds include unidentified acquisition deployment.

Pramodini Medicare IPO — FAQs

What is Pramodini Medicare IPO?
Pramodini Medicare IPO is a Small and Medium Enterprise (SME) initial public offering listing on NSE SME. The issue opens on — and closes on — with a price band of TBA per share.
What is the Pramodini Medicare IPO price band?
The price band for Pramodini Medicare IPO is TBA per equity share of face value ₹10 (typical). Retail investors are recommended to bid at the upper band (cut-off price).
What is the Pramodini Medicare IPO lot size?
The minimum lot size for Pramodini Medicare IPO is TBA shares per application. Minimum retail investment at the upper price band works out to approximately TBA.
When is the Pramodini Medicare IPO opening date?
Pramodini Medicare IPO opens for subscription on — and closes on —.
When is the Pramodini Medicare IPO allotment date?
Basis of allotment is expected on —. Check your status on Purva Sharegistry India's website using your PAN.
When is the Pramodini Medicare IPO listing date?
Pramodini Medicare shares are expected to list on NSE SME on —.
What is the GMP of Pramodini Medicare IPO?
GMP for Pramodini Medicare is not currently tracked.
Who is the registrar of Pramodini Medicare IPO?
Purva Sharegistry India is handling allotment, refunds, and dematerialisation for Pramodini Medicare IPO.
How can I apply for Pramodini Medicare IPO?
Apply via any SEBI-registered broker (Zerodha, Upstox, Angel One, Groww, 5paisa, ICICI Direct) during the open window. Use UPI mandate or ASBA for fund blocking. Bid at cut-off for retail category.
What is the minimum investment?
Minimum retail investment is approximately TBA (1 lot × TBA shares at upper band).
Should I apply for Pramodini Medicare IPO?
Whether to apply depends on your goals, risk appetite, and the company's fundamentals. Review the RHP, compare valuation with peers, and consult a SEBI-registered advisor.
What happens if my allotment fails?
Bid amount blocked via UPI/ASBA is released back within 24-48 hours. Apply through multiple family demat accounts to improve odds on oversubscribed issues.

Information shown is for educational purposes and does not constitute investment advice. GMP values are unofficial estimates from informal grey market sources. Please read the offer document (Red Herring Prospectus) carefully before investing.

Data sourced from NSE, BSE, the issue's registrar, and public filings. BasicFintech is not affiliated with the issuing company, its underwriters, or the exchanges.

GMP TodayAllotmentOpen Demat